TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas

Modern Pathology

Volumn 13, Issue 1, 2000, Pages 52-55

  Lyle, Stephen ^a   Salhany, Kevin E ^a   Elder, David E ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Melanoma; TIA 1; Tumor infiltrating lymphocytes

Indexed keywords

CD45 ANTIGEN; CELL MARKER;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CARCINOGENESIS; CYTOTOXIC T LYMPHOCYTE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA; NEVUS; PRIORITY JOURNAL; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 0033973678     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880009     Document Type: Article

References (17)

1. Clark WH, Elder DE, Guerry DPIV, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-904.
2. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
3. Pritchard ML, Woosley JT. Comparison of two prognostic models predicting survival in patients with malignant melanoma. Hum Pathol 1995;26:1028-31.
4. Mihm MC, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996;74:43-7.
5. Lowin B, Pieatsch MC, Tschopp J. Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Curr Top Microbiol Immunol 1995;198:1-24.
6. Berke G. The CTL's kiss of death. Cell 1995;81:9-12.
7. Anderson P, Nagler-Anderson C, O'Brien C, Levine H, Watkins S, Slayter HS, et al. A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. J Immunol 1990;144:574-82.
8. Anderson P. TIA-1: structural and functional studies on a new class of cytolytic effector molecule. Curr Top Microbiol Immunol 1995;198:131-43.
9. Tian Q, Streuli M, Saito H, Schlossman SF, Anderson P. A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell 1991;67:629-39.
10. Szymik B, Woosley JT. Further validation of the prognostic model for stage I malignant melanoma based on tumor progression. J Cutan Pathol 1993;20:50-3.
11. Elder DE, Van Belle P, Elenitsas R, Halpern Q, Gerry D. Neoplastic progression and prognosis in melanoma. Sem Cut Med Surg 1996;4:336-48.
12. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988;319:1676-80.
13. Crowley NJ, Slingluff CL, Vervaert CE, Darrow TL, Seigler HF. Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells. J Surg Oncol 1990;43:67-72.
14. Sabzevari H, Reisfeld RA. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice. Cancer Res 1993;53:4933-7.
15. Leong SPL, Zhou Y-M, Granberry ME, Wang TF, Grogan TM, Spier C, et al. Generation of cytotoxic effector cells against human melanoma. Cancer Immunol Immunother 1995;40: 397-409.
16. Schiltz PM, Beutel LD, Nayak SK, Dillman RO. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J Immunother 1997;20:377-86.
17. Reali UM, Martini L, Borgognoni L, Semino C, Pietra G, Chiarugi C, et al. Infusion of in vitro expanded tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma. Melanoma Res 1998;8:77-82.